NGM Biopharmaceuticals Inc (NGM) USD0.001
NGM Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics based on scientific understanding of key biological pathways underlying liver and metabolic diseases, retinal diseases and cancer. The Company’s product candidates include Aldafermin, MK-3655, NGM621, NGM120, NGM707 and NGM438. Aldafermin is an engineered variant of the human hormone FGF19, which the Company is developing treatment for non-alcoholic steatohepatitis (NASH). MK-3655 is an agonistic antibody binding to fibroblast growth factor receptor 1c-beta-klotho, or FGFR1c/KLB and has the potential as an insulin sensitizer for the treatment of NASH. It is also developing NGM831 a novel antagonist antibody designed to block the interaction of ILT3 of fibronectin, as well as with other ligands.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.